PDS, Biotechnology

PDS Biotechnology Shares Jump as Nant-Led Financing Takes Shape and Losses Narrow

Published on 11/16/2026 at 19:41 | Editorial boerse-global.de
PDS Biotechnology posted a $7.6M Q3 loss and confirmed the first close of a Nant Capital-led financing worth up to $22.3M; shares rose 13%.
PDS Biotechnology Corp Illustration mit AI erstellt.

PDS Biotechnology drew fresh investor attention on Friday after disclosing a narrower third-quarter loss and confirming the first close of a private financing led by Nant Capital worth up to $22.3 million. The stock climbed 13% on the day, with the financing news and quarterly figures landing together.

The company posted a net loss of $7.6 million for the third quarter of 2026, an improvement on the $9.0 million shortfall recorded in the same period a year earlier. On a per-share basis, the loss came to $0.11, compared with $0.19 in the prior-year quarter.

Financing Structure and FDA Milestone

The capital raise is structured as a private investment in public equity. According to the company, a further tranche hinges on PDS Biotechnology submitting a protocol to the FDA for a registrational Phase 3 trial of PDS0301. The headline figure of up to $22.3 million therefore should not be read as cash already in hand.

Should investors sell immediately? Or is it worth buying PDS Biotechnology Corp?

Research and development spending fell sharply, with $2.1 million booked in the third quarter of 2026 versus $4.6 million a year earlier. As of September 30, 2026, the company held cash and cash equivalents of $15.2 million — a balance struck at the quarter-end reporting date.

The quarterly report also came with an arrangement covering PDS0101: PDS Biotechnology granted NantWorks an exclusive one-year right to negotiate a license. The company said it would keep its focus squarely on PDS0301 as it presented the results, which were also filed with the SEC on Friday.

Warrant Exercise Adds Cash

Days before the quarterly update, on November 10, PDS Biotechnology had already flagged that NantWorks exercised warrants covering roughly 17.7 million common shares, or pre-funded warrants in lieu of the stock. The exercise price was $0.22 per share, generating gross proceeds of about $3.9 million for the company. That funding was announced after the balance-sheet date of the quarter just reported.

In a separate ownership filing following the exercise, Nant Capital, LLC reported holding approximately 22.9 million PDS Biotechnology shares, alongside about 30.2 million pre-funded warrants. The filing also described a cap limiting its economic stake to 19.9%.

Ad

PDS Biotechnology Corp Stock: New Analysis - 16 November

Fresh PDS Biotechnology Corp information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated PDS Biotechnology Corp analysis...

Disclaimer...
en | US70465T1079 | PDS | boerse | 70522375 |